
Mark B Leick

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8670369/publications.pdf Version: 2024-02-01



MADE RIFICE

#	Article	IF	CITATIONS
1	A glimpse into what happens after PTCy. Blood, 2022, 139, 479-481.	1.4	0
2	Antibody and T-cell responses to SARS-CoV-2 vaccination in myeloproliferative neoplasm patients. Leukemia, 2022, 36, 1176-1179.	7.2	3
3	Paraneoplastic Pulmonary Alveolar Proteinosis. American Journal of Respiratory and Critical Care Medicine, 2022, , .	5.6	0
4	Differential T cell immunity to SARS-CoV-2 in mRNA-1273 and BNT162b2 vaccinated individuals. Clinical Infectious Diseases, 2022, , .	5.8	6
5	Blockade or Deletion of IFNÎ ³ Reduces Macrophage Activation without Compromising CAR T-cell Function in Hematologic Malignancies. Blood Cancer Discovery, 2022, 3, 136-153.	5.0	46
6	Safety and efficacy of tisagenlecleucel in primary CNS lymphoma: a phase 1/2 clinical trial. Blood, 2022, 139, 2306-2315.	1.4	62
7	CAR T cell killing requires the IFNÎ ³ R pathway in solid but not liquid tumours. Nature, 2022, 604, 563-570.	27.8	150
8	Non-cleavable hinge enhances avidity and expansion of CAR-T cells for acute myeloid leukemia. Cancer Cell, 2022, 40, 494-508.e5.	16.8	54
9	Abstract 3575: Differential dynamics of response at single cell resolution between axi-cel and tisa-cel CAR-T therapy in refractory B-cell lymphomas. Cancer Research, 2022, 82, 3575-3575.	0.9	0
10	Abstract 569: Mesothelin CAR T cells secreting FAP specific T cell engaging molecule (TEAM) target pancreatic cancer and its tumor microenvironment (TME). Cancer Research, 2022, 82, 569-569.	0.9	0
11	Clinical Perspective: Treatment of Aggressive B Cell Lymphomas with FDA-Approved CAR-T Cell Therapies. Molecular Therapy, 2021, 29, 433-441.	8.2	22
12	Clonal hematopoiesis in patients receiving chimeric antigen receptor T-cell therapy. Blood Advances, 2021, 5, 2982-2986.	5.2	45
13	221â€CRISPR screen identifies loss of IFNγR signaling and downstream adhesion as a resistance mechanism to CAR T-cell cytotoxicity in solid but not liquid tumors. , 2021, 9, A234-A234.		0
14	Antibody and T-Cell Responses to COVID-19 Vaccination in Myeloproliferative Neoplasm Patients. Blood, 2021, 138, 316-316.	1.4	1
15	Effects of Prior Exposure to Tec Kinase(BTK/ITK) Inhibitors on Kte-X19 Products. Blood, 2021, 138, 3849-3849.	1.4	3
16	Rational Chemical and Genetic Modifications Enhance Avidity and Function of CD70-Directed CAR-T-Cells for Myeloid Leukemia. Blood, 2021, 138, 405-405.	1.4	1
17	Posttransplant cyclophosphamide in allogeneic bone marrow transplantation for the treatment of nonmalignant hematological diseases. Bone Marrow Transplantation, 2020, 55, 758-762.	2.4	7
18	Cell-based artificial APC resistant to lentiviral transduction for efficient generation of CAR-T cells from various cell sources. , 2020, 8, e000990.		13

MARK B LEICK

#	Article	IF	CITATIONS
19	Telephone. New England Journal of Medicine, 2020, 383, 2304-2305.	27.0	2
20	T Cell Clonal Dynamics Determined by High-Resolution TCR-β Sequencing in Recipients after Allogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2020, 26, 1567-1574.	2.0	11
21	CAR-T cells secreting BiTEs circumvent antigen escape without detectable toxicity. Nature Biotechnology, 2019, 37, 1049-1058.	17.5	347
22	Tisagenlecleucel CAR T-cell therapy in secondary CNS lymphoma. Blood, 2019, 134, 860-866.	1.4	178
23	Case 35-2019: A 66-Year-Old Man with Pancytopenia and Rash. New England Journal of Medicine, 2019, 381, 1951-1960.	27.0	7
24	Wishing on a CAR: Understanding the Scope of Intrinsic T-cell Deficits in Patients with Cancer. Cancer Discovery, 2019, 9, 466-468.	9.4	8
25	CRISPR-Cas9 disruption of PD-1 enhances activity of universal EGFRvIII CAR T cells in a preclinical model of human glioblastoma. , 2019, 7, 304.		181
26	CARâ€T cells beyond CD19, UnCARâ€Ted territory. American Journal of Hematology, 2019, 94, S34-S41.	4.1	6
27	Use of CD70 Targeted Chimeric Antigen Receptor (CAR) T Cells for the Treatment of Acute Myeloid Leukemia (AML). Blood, 2019, 134, 4443-4443.	1.4	6
28	Application of a Standardized Flow Cytometry Panel for Defining and Monitoring the Immunophenotype of CAR-T Cells. Blood, 2019, 134, 5626-5626.	1.4	1
29	Post-Transplant Cyclophosphamide in Allogeneic Bone Marrow Transplantation for the Treatment of Benign Hematologic Diseases. Blood, 2019, 134, 1978-1978.	1.4	Ο
30	Toxicities associated with immunotherapies for hematologic malignancies. Best Practice and Research in Clinical Haematology, 2018, 31, 158-165.	1.7	14
31	The Future of Targeting FLT3 Activation in AML. Current Hematologic Malignancy Reports, 2017, 12, 153-167.	2.3	38
32	HIV and Indolent Lymphoma. , 2016, , 107-117.		0
33	Dose-finding study of hepatic arterial infusion of oxaliplatin-based treatment in patients with advanced solid tumors metastatic to the liver. Cancer Chemotherapy and Pharmacology, 2013, 71, 389-397.	2.3	13
34	Loss of imprinting of IGF2 and the epigenetic progenitor model of cancer. American Journal of Stem Cells, 2012, 1, 59-74.	0.4	30